GE HealthCare Technologies Inc. (GEHC)
GEHC Q2 Orders Surge 11.1% as Record Backlog Builds 2027 Visibility
GEHC's 11.1% order growth and record $23.9B backlog improve revenue visibility, but PCS execution and inflation remain key constraints.
Is GEHC a Buy Now as Growth Improves but Execution Risks Persist?
GEHC's valuation discount and growth in imaging and diagnostics support the case, but PCS weakness, inflation and debt keep execution risks elevated.
Here's Why You Should Add GEHC Stock to Your Portfolio for Now
GE HealthCare's record backlog, strong Pharmaceutical Diagnostics growth and AI innovation support its growth outlook despite margin pressures.
GEHC or LMAT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
GE HealthCare (GEHC) Upgraded to Buy: Here's What You Should Know
GE HealthCare (GEHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GE HealthCare Technologies (GEHC) Just Overtook the 200-Day Moving Average
GE HealthCare Technologies (GEHC) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GEHC broke through the 200-day moving average, which suggests a long-term bullish trend.
Here's Why GE HealthCare Technologies (GEHC) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GE HealthCare: Strong Orders, Innovation Pipeline, And PCS Recovery Point To Growth Inflection
GE HealthCare Technologies (GEHC) is rated Buy, with risk-reward attractive due to accelerating growth and an undervalued multiple versus peers. Order growth, backlog expansion, and a robust innovation pipeline position GEHC for revenue acceleration and margin improvement as new products scale. Patient Care Solutions business is expected to recover as supply chain issues resolve, supporting overall growth and margin rebound.
Why GE HealthCare Technologies (GEHC) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GE HealthCare: Strong Demand, Weak Execution - Why The Backlog Matters More (Rating Upgrade)
GE HealthCare Technologies is upgraded to Buy, driven by robust 11% YoY orders growth, a record $23.9B backlog, and strong forward visibility. GEHC's demand strength is structural, with AI-enabled imaging and theranostics innovation expected to accelerate revenue and margin expansion into 2027 and beyond. The Patient Care Solutions segment is a temporary drag due to supply chain issues, but backlog and demand remain intact, positioning for recovery as constraints ease.
GEHC Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
GE HealthCare beats second-quarter estimates as revenues rise 5.7%, orders climb 11.1% and backlog hits a record $23.9 billion.
GE HealthCare Technologies Inc. (GEHC) Q2 2026 Earnings Call Transcript
GE HealthCare Technologies Inc. (GEHC) Q2 2026 Earnings Call Transcript
